Brought to you by 
Molecular Staging gets $41.25mm with Series D financing
09 Jan 2001
Executive Summary
Molecular Staging (tools to detect and measure proteins) has raised $41.25mm with the private placement of Series D preferred stock. Investor AB's Investor Growth Capital--which contributed $20mm--was joined by OrbiMed, CIBC Capital Partners, and Cooper Hill Partners. Existing investors Domain Partners, CHL Medical Partners, and 3i Bioscience Investment also participated.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Molecular Staging gets $41.25mm with Series D financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice